Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 7/20 | 0.58 |
| ▸ | MMP2 | P08253 | 13/20 | 0.48 |
| ▸ | MMP9 | P14780 | 11/20 | 0.48 |
| ▸ | MMP13 | P45452 | 9/20 | 0.48 |
| ▸ | MMP7 | P09237 | 8/20 | 0.48 |
| ▸ | MMP3 | P08254 | 8/20 | 0.48 |
| ▸ | MMP8 | P22894 | 7/20 | 0.48 |
| ▸ | MMP14 | P50281 | 7/20 | 0.48 |
| ▸ | MMP1 | P03956 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23752597 | 0.94 | MMP2 (0.49) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL2353236 | 0.94 | MMP2 (0.49) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL2354755 | 0.89 | POLB (0.48) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL2353443 | 0.87 | MMP2 (0.49) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL2352197 | 0.86 | ADAMTS4 (0.42) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL2354741 | 0.85 | SLC1A3 (0.41) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL2349607 | 0.84 | NPSR1 (0.52) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL2353824 | 0.84 | SLC1A3 (0.43) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL23752492 | 0.83 | ANPEP (0.41) | ADAMTS4MMP2MMP9MMP13MMP7 | |
| SCHEMBL23752491 | 0.83 | ANPEP (0.41) | ADAMTS4MMP2MMP9MMP13MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4472997-B2 | — | — | 2010-06-02 | — | — | JP | claimed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | claimed |
| EP-1817041-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | claimed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | claimed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | claimed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | claimed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | claimed |
| JP-2006504622-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | claimed |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | disclosed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | disclosed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SERPINB1, TFPI, TFPI2 | ADAMTS4 168/4885MMP2 79/4885MMP9 115/4885 |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | CPB1, CPB2, CPA1 | ADAMTS4 157/4885MMP2 110/4885MMP9 151/4885 |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | CPB1, CPB2, CPA1 | ADAMTS4 157/4885MMP2 110/4885MMP9 151/4885 |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | TFPI, TFPI2, TNNI3 | ADAMTS4 245/4885MMP2 532/4885MMP9 468/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | ADAMTS4 179/4885MMP2 114/4885MMP9 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.